HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Lauren Nardella

Lauren Nardella covers health care business topics, including contributions for more than a decade to HBW Insight (and previously the Rose Sheet) for more than a decade, where’s she has covered the regulation, business, science and policy of the cosmetics and personal-care products industries. She enjoys tackling complex issues and turning them into stories that help readers stay abreast of current topics. Nardella was previously a business reporter for various daily newspapers. She lives in Northern Virginia.

Latest From Lauren Nardella

The Replacements: Cosmetic Ingredient Suppliers At Ready With Microplastic Alternatives As EU Ban Unfolds

HBW Insight reached out to suppliers of microplastic alternatives for cosmetics use to discuss their offerings and preparedness for demand surges under phased REACH prohibitions.

Regulation Cosmetic Ingredients

Akili Awaits FDA Feedback On Data Needs For OTC Marketing Of ADHD Digital Therapeutic

The DTx company’s revenue grew some 500% to $702,000 in the fiscal 2023 third quarter, reflecting its direct-to-consumer launch of EndeavorOTC to adult ADHD patients in June under a US FDA enforcement policy established for digital health devices during the COVID-19 public health emergency. That policy has since sunset, and Akili has submitted a 510(k) application to the agency for review.

Digital Health FDA

Akili Awaits FDA Feedback On Data Needs For OTC Marketing Of ADHD Digital Therapeutic

The DTx company’s revenue grew some 500% to $702,000 in the fiscal 2023 third quarter, reflecting its direct-to-consumer launch of EndeavorOTC to adult ADHD patients in June under a US FDA enforcement policy established for digital health devices during the COVID-19 public health emergency. That policy has since sunset, and Akili has submitted a 510(k) application to the agency for review.

Digital Health FDA

US FDA Chief Scientist Bumpus Takes On Health Disparities, Formaldehyde In Hair Straighteners

New leadership overseeing the US Food and Drug Administration’s Office of Cosmetics and Colors has kickstarted a long-sought rulemaking to address formaldehyde and formaldehyde releasers in hair straightening products, with a proposed ban in mind.

FDA Cosmetic Ingredients

Information Deluge Headed US FDA’s Way When Cosmetics Registration Portal Opens

In comments on FDA draft guidance released in August, industry members raise questions about the agency’s capacity to deal with an anticipated flood of facility registrations and product listings. Confidentiality and international trade also figure among concerns.

FDA Regulation

CIR On MoCRA Product Listing: FDA Should Refine Categories For Optimal Data Collection

Cosmetic product/ingredient listing required by new cosmetics regulations will be a boon for CIR, which has conducted its ingredient reviews to date based on limited, voluntary data reporting. Adding new product classifications and subcategories to the US FDA’s listing system could provide needed insight into dry shampoo and other product formats and help identify potential for incidental inhalation risks.

FDA Regulation
See All
UsernamePublicRestriction

Register